Is Cibinqo affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Cibinqo is affected by pharmacogenetics through the CYP2C19 gene. Your genotype for this gene can change how your body processes Cibinqo, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Cibinqo

abrocitinib affected by CYP2C19

Affected by CYP2C19 · FDA · Strong evidence

Read the full abrocitinib genetics guide →

Abrocitinib phenotype recommendations

Published guidance from FDA on how abrocitinib should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	"Your body breaks down the medication abrocitinib very fast. As of now, there are no special instructions for people with this trait. Your doctor will guide you with the usual dosage and usage of this medicine."	FDA Abrocitinib - label recommended dosage and administration	Strong
Rapid Metabolizer CYP2C19	"Your body breaks down the medication abrocitinib quite quickly. Your doctor will follow the standard dose and administration instructions for this medication."	FDA Abrocitinib - label recommended dosage and administration	Strong
Normal Metabolizer CYP2C19	Your body processes the drug abrocitinib normally. Standard dosing guidelines are recommended.	FDA Abrocitinib - label recommended dosage and administration	Strong
Intermediate Metabolizer CYP2C19	"Your body may process abrocitinib at a slightly slower rate. Your doctor will continue to follow the standard dosage instructions, but will closely monitor your response to the medication."	FDA Abrocitinib - label recommended dosage and administration	Moderate
Poor Metabolizer CYP2C19	"Your body may process abrocitinib slower than expected, which could increase risk of side effects. Your doctor may reduce your dose to ensure the medication works well for you."	FDA Results in higher systemic concentrations and may result in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	Strong
Likely Intermediate Metabolizer CYP2C19	"Based on your genetic result, your body may process abrocitinib at a slower than average rate. However, there's no need for making changes to the usual dosage recommended on the label, according to these results."	FDA Abrocitinib - label recommended dosage and administration	Moderate
Likely Poor Metabolizer CYP2C19	"Your body may not break down the drug abrocitinib as effectively, which could increase side effects. Your doctor may suggest changing your dosage to suit you better."	FDA Results in higher systemic concentrations and may result in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	Strong
Indeterminate CYP2C19	Your genetic test result does not give a clear answer on how your body processes abrocitinib.	FDA Abrocitinib - label recommended dosage and administration	—
Not available CYP2C19	Your genetic test result does not give a clear answer on how your body processes abrocitinib.	FDA Abrocitinib - label recommended dosage and administration	—

Source: FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Browse the full drug-class: Immunosuppressants.

Related medications

Find out how your genetics affect Cibinqo

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.